Telehealth-Guided Virtual Reality for Recovery of Upper Extremity Function Following Stroke.

Only 21 participants were enrolled and 18 completed, well below the originally planned sample. The study was stopped early when the funding grant ended. The control group received usual and customary care, not a matched-dose alternative therapy, so the finding shows an incremental benefit on top of normal care rather than superiority over an equally intensive program. Participants all had at least some active arm and finger movement (minimum 45 degrees elbow flexion, detectable finger flexion). The result does not apply to patients with a completely flaccid or severely spastic arm. Enrollment occurred during the pandemic, and the authors note that volunteers may have been more motivated to adhere to a home program than the average stroke survivor. The analysis adjusted only for baseline score and time since stroke; other potential confounders were not included.

The study was funded by the NIH (NICHD). Richard Adams, a co-author, is a salaried employee of Barron Associates, Inc., the for-profit company that owns the intellectual property in the GRASP system and was the grantee. Barron Associates also paid another co-author as a consultant. The glove used is a commercial SaeboGlove product. The system is a second-generation prototype, not yet a standalone commercial product.

Do not read this as proof that virtual reality beats in-person therapy. The control group received usual and customary care, not a matched-dose alternative, and all participants had at least some active arm and finger movement. The finding is that adding this home program to normal care produced extra gain, not that it replaces clinic-based therapy or works for the most severely affected arms.